c-Maf expression in angioimmunoblastic T-cell lymphoma.
The oncogene c-Maf was recently found to be overexpressed in approximately 50% of multiple myeloma cases, and a role for c-Maf in promoting cyclin D2 expression has been postulated. We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT). In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically. Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type. Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26). Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples. Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test). These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
Department of Pathology of Biological Response, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Japan. yidate@med.nagoya-u.ac.jp
Yoshiko Idate
YI
Murakami
Yasushi
Y
Yatabe
Teruhiro
T
Sakaguchi
Eiichi
E
Sasaki
Yoriko
Y
Yamashita
Naoki
N
Morito
Keigyou
K
Yoh
Yuuki
Y
Fujioka
Fumihiko
F
Matsuno
Hiroyuki
H
Hata
Hiroaki
H
Mitsuya
Shigehiko
S
Imagawa
Atsushi
A
Suzuki
Hiroyasu
H
Esumi
Masaharu
M
Sakai
Satoru
S
Takahashi
Naoyoshi
N
Mori
D000328:Adult; D018951:Antigens, CD20 / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D015704:CD4 Antigens / Q000032:analysis; D056741:Cyclin D; D056742:Cyclin D2; D016213:Cyclins / Q000032:analysis; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D007150:Immunohistochemistry; D017493:Leukocyte Common Antigens / Q000032:analysis; D051917:Leukosialin / Q000032:analysis; D016399:Lymphoma, T-Cell / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D051257:Proto-Oncogene Proteins c-maf / Q000032:analysis* / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015854:Up-Regulation
D018951:Antigens, CD20; D014408:Biomarkers, Tumor; C080336:CCND2 protein, human; D015704:CD4 Antigens; D056741:Cyclin D; D056742:Cyclin D2; D016213:Cyclins; D051917:Leukosialin; C495607:MAF protein, human; D051257:Proto-Oncogene Proteins c-maf; D012333:RNA, Messenger; C465014:SPN protein, human; D017493:Leukocyte Common Antigens